Rivenprost
Based on 1 Customer Validation
Rivenprost (ONO-4819; ONO-AE1-734) is a selective agonist for prostaglandin E receptor EP4 with Ki of 0.7 nM. Rivenprost exhibits hepatoprotective and bone anabolic effects.
The product specifications provided below refer solely to the active content of Rivenprost.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.0%
- No. CAS: 256382-08-8
- Fòrmula: C24H34O6S
- Peso molecular:450.59
-
Almacenamiento:
Solution, -20°C, 2 years
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
Descripciòn
IC50 & Target
|
EP4 0.7 nM (Ki) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO | EC50 |
1.6 nM
Compound: 52, ONO-4819
|
Agonist activity at mouse EP4 receptor expressed in CHO cells assessed as cAMP production
Agonist activity at mouse EP4 receptor expressed in CHO cells assessed as cAMP production
|
[PMID: 20218623] |
In Vitro
Rivenprost (1 nM–1 μM) stimulates the osteoblast differentiation through upregulation of Runx2 and Osterix, leading to increased bone formation[1].
Rivenprost (1 nM–1 μM) inhibits the adipocytes differentation in bone by downregulating the mRNA expression of PPARγ[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:C3H10T1/2
-
Concentration:1 nM–1 μM
-
Incubation Time:7 days
-
Result:Reduced PPARγ in a dose-dependent manner.
In Vivo
Rivenprost (0.2 mg/kg, i.p., single dosage) exhibits hepatoprotective efficacy towards GalN-/LPS-induced liver injury in wistar rats through inflammatory cytokines such as TNF-α[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague Dawley rats[1]
-
Dosage:10 μg/kg
-
Administration:s.c., twice a day for 5 weeks
-
Result:Increased osteoblast number, bone volume, mineral apposition rate and bone formation rate.
Decreased adipocyte number.
-
Animal Model:GalN/LPS-induced acute liver injury in wistar rats[2]
-
Dosage:0.2 mg/kg
-
Administration:i.p., single dosage
-
Result:Inhibited development of hepatic necrosis, decreased levels of AST, ALT, TNF-α and IFN-γ.
Ensayo clínico
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 256382-08-8
-
Appearance Liquid
-
Peso molecular 450.59
-
Fòrmula C24H34O6S
-
Color Colorless to light yellow
-
SMILES
COCC1=CC=CC(C[C@H](O)/C=C/[C@@H]2[C@H](C(C[C@H]2O)=O)CCSCCCC(OC)=O)=C1
-
Synonyms
ONO-4819; ONO-AE1-734
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Solution, -20°C, 2 years
Pureza y Documentación
-
Ficha de datos (289 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Ninomiya T, et al., Prostaglandin E(2) receptor EP(4)-selective agonist (ONO-4819) increases bone formation by modulating mesenchymal cell differentiation. Eur J Pharmacol. 2011 Jan 10;650(1):396-402. [Content Brief]
[2]. Kasai K, et al., A novel prostaglandin E receptor subtype agonist, 0N0-4819, attenuates acute experimental liver injury in rats. Hepatol Res. 2001 Nov;21(3):252-260. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Rivenprost Related Classifications
HY-114974 Related Classifications
Powered by Bioz